Detalhe da pesquisa
1.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357801
2.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol
; 23(6): 781-792, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576957
3.
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Oncologist
; 25(3): e451-e459, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162804
4.
Monoclonal gammopathy of thrombotic/thrombocytopenic significance.
Blood
; 141(14): 1772-1776, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626584
5.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31122901
6.
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Lung Cancer
; 190: 107512, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417277
7.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
J Clin Oncol
; 41(6): 1213-1227, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36327426
8.
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol
; 18(11): 1594-1606, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390980
9.
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Lung Cancer
; 186: 107422, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992595
10.
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Cancer Discov
; 13(11): 2394-2411, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37707791
11.
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Cancer Manag Res
; 13: 6207-6218, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34408488
12.
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Adv Ther
; 38(1): 350-365, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33123968
13.
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
J Thorac Oncol
; 15(8): 1351-1360, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32302702
14.
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
J Clin Oncol
; 38(33): 3863-3873, 2020 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910710
15.
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
J Thorac Oncol
; 14(9): 1628-1639, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121324
16.
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Clin Lung Cancer
; 25(3): 266-273.e5, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38584069
17.
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
J Thorac Oncol
; 12(1): 110-120, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27639678
18.
Approach to anemia.
Dis Mon
; 56(8): 449-55, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20800754